Project Grant R37AI189855
- This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $693,465 to Cornell University over a period from January 2025 to December 2029. The funding supports a research project titled "Mapping Infant and Adult T Cell Immunity" that aims to construct a molecular atlas of T cell development in lymph nodes and determine how cellular interactions and communication networks change during CD8+ T...
- This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports fundamental immunological research at the University of Toledo Health Science Campus Division. The award of $162,000 obligated on September 1, 2025, with completion targeted for August 31, 2027, funds research to elucidate the cardioprotective role of fetal-derived CD8+ T cells during viral-induced myocarditis....
- Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Rochester a $1.042 million Project Grant (CFDA 93.855—Allergy and Infectious Diseases Research) on January 28, 2026, to conduct research on critical developmental windows and underlying processes in extremely low gestational age neonates' immune trajectories through December 31, 2030. The project addresses a significant gap in understanding fetal and postnatal immune development in extremely...
- Summary Yale University received a $5.87 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) awarded July 23, 2025, with completion targeted for May 31, 2030. The grant funds the "Predictors and Determinants of Pediatric Immunity" (PEDS) program, a multi-project research initiative designed to characterize the unique biology of the pediatric immune system and establish...
- Federal Grant Award Summary Cornell University's Office of Sponsored Programs received a Project Grant of $238,810 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on September 1, 2025, with completion scheduled for August 31, 2027. The research project, titled "Embryonic Origins of T Cells," addresses fundamental gaps in understanding T lymphocyte development and function. The grant...
- The Leland Stanford Junior University received a $153,512 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective December 13, 2025, with a completion date of June 30, 2026. This research initiative will develop a comprehensive immune cell atlas of kidney tissues affected by antibody-mediated rejection (ABMR) using advanced imaging mass cytometry technology. The project will...
- Federal Project Grant Award Summary Cincinnati Children's Hospital Medical Center received a $202,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded June 16, 2026, with a completion date of May 31, 2028. The grant funds research examining the role of peroxisomes and peroxisomal fatty acid beta-oxidation (PFABO) in regulating CD4+ T cell inflammatory responses and immune-related...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $267,000 Project Grant on April 16, 2026, to Boston Children's Hospital to support basic immunological research focused on elucidating the molecular mechanisms of AIRE (Autoimmune Regulator) in transcriptional regulation. The grant, funded under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a 24-month research initiative (completion date March 31,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded The Trustees of Columbia University in the City of New York $3.14 million on February 6, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a four-year research project on regulatory T cell (Treg) memory in human tissues through January 31, 2030. This project will deliver biomedical research services focused on understanding how antigen-specific...
- Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded Northwestern University $627,462 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 7, 2025, for a project period extending through July 31, 2030. The research initiative focuses on understanding T cell exhaustion mechanisms in chronic viral infection through advanced molecular and cellular analysis techniques. The investigator's team will utilize paired single-cell RNA...
MAPPING INFANT AND ADULT T CELL IMMUNITY - PROJECT SUMMARY / ABSTRACT THE PRIMING OF CD8+ T CELLS IN THE LYMPH NODE ULTIMATELY DETERMINES THE SUCCESS OF THE HOST RESPONSE TO INTRACELLULAR PATHOGENS. PRIMING DETERMINES WHETHER THE PATHOGEN IS CLEARED BY EFFECTOR T CELLS AND IMMUNITY IS ESTABLISHED BY MEMORY CELLS. DESPITE THE IMPORTANCE OF THIS KEY STEP, OUR UNDERSTANDING OF THE EVENTS THAT OCCUR IN THE LYMPH NODE EARLY AFTER INFECTION IS STILL CONSIDERED A BLACK BOX AND IS LARGELY BASED ON STUDIES PERFORMED IN ADULT ANIMALS. INDEED, THERE IS ALMOST NO INFORMATION AVAILABLE ON HOW THE LYMPH NODES CHANGE FROM BIRTH TO ADULTHOOD. AS A RESULT, WE DO NOT UNDERSTAND HOW T CELLS BECOME ACTIVATED IN THE LYMPH NODE AT DIFFERENT STAGES OF LIFE, AND THE LACK OF SUCH INFORMATION HAS MADE IT DIFFICULT TO DEVELOP NEW STRATEGIES TO ENHANCE IMMUNITY IN EARLY LIFE. USING NEW TECHNOLOGY, WE PLAN TO CONSTRUCT THE FIRST MOLECULAR ATLAS OF T CELL DEVELOPMENT IN LYMPH NODES AND DETERMINE HOW THE CELLULAR INTERACTIONS AND COMMUNICATION NETWORKS CHANGE DURING CD8+ T CELL PRIMING THROUGHOUT CHILDHOOD. OUR HYPOTHESIS IS THAT CD8+ T CELLS MADE IN EARLY LIFE ARE LOCATED IN AN 'INNATE NICHE' NEAR THE SUBCAPSULAR MACROPHAGES AND HELP TO LIMIT TRANSNODAL SPREAD OF PATHOGENS DURING THE PRIMARY RESPONSE, WHEREAS CD8+ T CELLS MADE IN ADULTHOOD ARE FOUND IN AN 'ADAPTIVE NICHE' NEAR THE CENTRAL PARACORTEX AND ARE SUPERIOR AT PROVIDING SYSTEMIC PROTECTION TO SECONDARY INFECTIONS. IN THE FIRST AIM, WE WILL DETERMINE HOW THE SPATIAL ORGANIZATION OF T CELLS CHANGES IN THE LYMPH NODE THROUGHOUT CHILDHOOD. IN THE SECOND AIM, WE WILL EXAMINE HOW THE LYMPH NODE SHAPES THE CD8+ T CELL RESPONSE TO INFECTION IN INFANTS AND ADULTS. IN THE THIRD AIM, WE WILL EVALUATE THE IMPACT OF MICROBIAL EXPOSURE ON THE DEVELOPMENT AND FUNCTION OF LYMPHOID CD8+ T CELLS. THE OBTAINED RESULTS ARE EXPECTED TO PROVIDE THE RESEARCH COMMUNITY WITH A NEW PARADIGM FOR T CELL ACTIVATION AND AN INVALUABLE RESOURCE FOR UNDERSTANDING HOW IMMUNE RESPONSIVENESS CHANGES AT VARIOUS STAGES OF LIFE. THIS NEW ATLAS OF T CELL DEVELOPMENT HAS BROAD IMPLICATIONS FOR THE DESIGN OF MORE PRECISE IMMUNOTHERAPIES AND THE DEVELOPMENT OF MORE EFFECTIVE VACCINES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $713.7k | 1/23/26 | ||
| Not listed | $693.5k | 1/21/25 | ||
| Not listed | $693.5k | 1/21/25 |